Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
25 Julho 2023 - 9:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq:
CPRX) today announced that Patrick J. McEnany, Catalyst’s
Co-Founder, Chairman, and Chief Executive Officer ("CEO") has
informed the Board of Directors ("Board") of his intention to
retire from his position as CEO by the end of 2023. Mr. McEnany
remains the Company’s largest individual stockholder and will
continue to serve as CEO until his replacement is in place.
Thereafter following his retirement as CEO, Mr. McEnany will
continue to serve as non-Executive Chairman of Catalyst's Board of
Directors.
“I want to thank Pat for his tremendous
contributions to Catalyst as our Company’s Co-Founder and CEO for
the past 21 years,” said Charles O’Keeffe, Lead Independent
Director for Catalyst. “Under his leadership, Catalyst has
successfully transformed from a start-up into a formidable
biopharmaceutical company specializing in bringing FDA approved
therapies to patients suffering from rare neurological conditions.
He has overseen highly strategic acquisitions and partnerships by
Catalyst, fostered a high-performance culture and a highly engaged
team of associates at Catalyst. His work has shaped and solidified
the foundation from which our company will continue to build for
the future. We look forward to Pat’s continued leadership and
contribution as the Chairman of our Board of Directors.”
“It has been an exceptional privilege to be the
Co-Founder and CEO of Catalyst, which has provided me with the
unique opportunity to oversee and actively contribute to the
remarkable growth and substantial accomplishments that have driven
our company’s success over the past two decades. I am incredibly
proud of all we have achieved, and I look forward to continuing to
serve as Chairman of the Board and helping guide our collective
efforts for further growth,” stated Patrick J. McEnany, Co-Founder,
Chairman, and CEO of Catalyst. “While I am looking forward to this
next step, I want to thank our Board of Directors and my colleagues
for their sustained partnership as we continue to deliver on the
exceptional performance that is reshaping the future of the Company
for further success, as well as our dedicated team of employees
whose contributions and patient focus commitment have helped us
realize our business objectives. I also want to take this
opportunity to express gratitude to my incredible family for their
unwavering support in fulfilling the mission of helping patients
and our communities.”
The Company's Board of Directors has retained a
nationally recognized executive recruitment firm to initiate the
search for Mr. McEnany's successor as CEO. Once a successor has
been appointed, Mr. McEnany will assist in the transition from his
position as CEO and will continue to serve as non-executive
Chairman of the Board for Catalyst. This transition is designed to
provide leadership continuity and reflects the Company's commitment
to the continued execution of its business operations and strategic
growth initiatives.
About Catalyst
PharmaceuticalsWith exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's U.S. commercial product portfolio
consists of FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for
adults and children ages six to seventeen. In January 2023,
Catalyst acquired the U.S. commercial rights of FYCOMPA®
(perampanel) CIII, a prescription medicine approved in people with
epilepsy aged four and older alone or with other medicines to treat
partial-onset seizures with or without secondarily generalized
seizures, and with other medicines to treat primary generalized
tonic-clonic seizures for people with epilepsy aged 12 and older.
Further, Canada's national healthcare regulatory
agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023, Catalyst
acquired an exclusive license for North America for vamorolone, a
promising best-in-class dissociative anti-inflammatory steroid
treatment for patients suffering from Duchenne muscular dystrophy.
Vamorolone has received FDA Orphan Drug and Fast Track designations
and has been granted a PDUFA action date of October 26, 2023.
For more information, visit the Company's
website at www.catalystpharma.com. For Full Prescribing and
Safety Information for FIRDAPSE®, please
visit www.firdapse.com. For Full Prescribing Information,
including Boxed WARNING for FYCOMPA®, please
visit www.fycompa.com.
Forward-Looking StatementsThis
press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause Catalyst's actual results in future periods to differ
materially from forecasted results. A number of factors, including
(i) factors and uncertainties relating to the Company's
contemplated CEO transition, (ii) whether the new CEO selected will
have the desired level of experience and expertise, (iii) the
potential impact on Catalyst's business and future strategic
direction resulting from the CEO transaction, (iv) Catalyst's
ability to retain other key members of senior management following
the hiring of a new CEO, and (v) those factors described in
Catalyst's Annual Report on Form 10-K for the fiscal year 2022 and
its other filings with the U.S. Securities and Exchange
Commission ("SEC"), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from the SEC, may be
found on Catalyst's website, or may be obtained upon request
from Catalyst. Catalyst does not undertake any obligation to update
the information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman
Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024